A new antihypertensive drug ameliorate insulin resistance.
作者信息
Liu Yan-xia
机构信息
Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China.
出版信息
Acta Pharmacol Sin. 2012 Apr;33(4):429-30. doi: 10.1038/aps.2012.31.
Abstract
摘要
相似文献
1
A new antihypertensive drug ameliorate insulin resistance.一种新型抗高血压药物可改善胰岛素抵抗。
Acta Pharmacol Sin. 2012 Apr;33(4):429-30. doi: 10.1038/aps.2012.31.
2
The novel ATP-sensitive potassium channel opener iptakalim prevents insulin resistance associated with hypertension via restoring endothelial function.新型三磷酸腺苷敏感性钾通道开放剂伊帕立林可通过恢复内皮功能预防高血压相关的胰岛素抵抗。
Acta Pharmacol Sin. 2011 Dec;32(12):1466-74. doi: 10.1038/aps.2011.129. Epub 2011 Nov 7.
3
Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.ATP敏感性钾通道的激活可保护血管内皮细胞免受高尿酸血症诱导的高血压和肾损伤。
J Hypertens. 2008 Dec;26(12):2326-38. doi: 10.1097/HJH.0b013e328312c8c1.
4
Iptakalim: a new or just another KCO?埃他卡林：一种新型钾通道开放剂还是只是另一种钾通道开放剂？
Cardiovasc Res. 2009 Aug 1;83(3):417-8. doi: 10.1093/cvr/cvp193. Epub 2009 Jun 10.
5
Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim.以一种新的三磷酸腺苷敏感性钾通道开放剂伊帕立林靶向治疗高血压。
J Cardiovasc Pharmacol. 2010 Sep;56(3):215-28. doi: 10.1097/FJC.0b013e3181e23e2b.
6
K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.K(ATP)激活通过保护内皮功能来防止压力超负荷诱导的心脏肥大发展为心力衰竭。
Cardiovasc Res. 2009 Aug 1;83(3):444-56. doi: 10.1093/cvr/cvp099. Epub 2009 Mar 20.
7
exhibits Antihypertensive Activity through Activation of Vascular KATP Channels Activation in Rats.在大鼠中通过激活血管 KATP 通道表现出抗高血压活性。
Endocr Metab Immune Disord Drug Targets. 2020;20(5):736-744. doi: 10.2174/1871530319666191016100851.
8
SUR2B/Kir6.1 channel openers correct endothelial dysfunction in chronic heart failure via the miR-1-3p/ET-1 pathway.SUR2B/Kir6.1 通道开放剂通过 miR-1-3p/ET-1 通路纠正慢性心力衰竭中的内皮功能障碍。
Biomed Pharmacother. 2019 Feb;110:431-439. doi: 10.1016/j.biopha.2018.11.135. Epub 2018 Dec 5.
9
Activation of SUR2B/Kir6.1 subtype of adenosine triphosphate-sensitive potassium channel improves pressure overload-induced cardiac remodeling via protecting endothelial function.激活三磷酸腺苷敏感性钾通道 SUR2B/Kir6.1 亚基可通过保护内皮功能改善压力超负荷诱导的心脏重构。
J Cardiovasc Pharmacol. 2010 Oct;56(4):345-53. doi: 10.1097/FJC.0b013e3181e6c7b8.
10
The new antihypertensive drug iptakalim activates ATP-sensitive potassium channels in the endothelium of resistance blood vessels.新型抗高血压药物伊普卡林可激活阻力血管内皮细胞中的ATP敏感性钾通道。
Acta Pharmacol Sin. 2015 Dec;36(12):1444-50. doi: 10.1038/aps.2015.97. Epub 2015 Nov 23.
引用本文的文献
1
Applying Structural Equation Modelling to Understand the Implementation of Social Distancing in the Professional Lives of Healthcare Workers.运用结构方程模型理解医护人员专业生活中的社交距离实施情况。
Int J Environ Res Public Health. 2023 Mar 6;20(5):4630. doi: 10.3390/ijerph20054630.
本文引用的文献
1
Iptakalim: A novel multi-utility potassium channel opener.埃他卡林：一种新型多功能钾通道开放剂。
J Pharmacol Pharmacother. 2012 Jan;3(1):12-4. doi: 10.4103/0976-500X.92495.
2
The novel ATP-sensitive potassium channel opener iptakalim prevents insulin resistance associated with hypertension via restoring endothelial function.新型三磷酸腺苷敏感性钾通道开放剂伊帕立林可通过恢复内皮功能预防高血压相关的胰岛素抵抗。
Acta Pharmacol Sin. 2011 Dec;32(12):1466-74. doi: 10.1038/aps.2011.129. Epub 2011 Nov 7.
3
Association of the antihypertensive response of iptakalim with KCNJ11 (Kir6.2 gene) polymorphisms in Chinese Han hypertensive patients.中国汉族高血压患者伊帕立林降压反应与 KCNJ11（Kir6.2 基因）多态性的关联。
Acta Pharmacol Sin. 2011 Aug;32(8):1078-84. doi: 10.1038/aps.2011.85. Epub 2011 Jul 18.
4
Chemerin/ChemR23 signaling axis is involved in the endothelial protection by K(ATP) channel opener iptakalim.Chemerin/ChemR23 信号轴参与由 KATP 通道开放剂伊帕立林引起的内皮保护作用。
Acta Pharmacol Sin. 2011 May;32(5):573-80. doi: 10.1038/aps.2011.19. Epub 2011 Apr 25.
5
Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim.以一种新的三磷酸腺苷敏感性钾通道开放剂伊帕立林靶向治疗高血压。
J Cardiovasc Pharmacol. 2010 Sep;56(3):215-28. doi: 10.1097/FJC.0b013e3181e23e2b.
6
Iptakalim: a new or just another KCO?埃他卡林：一种新型钾通道开放剂还是只是另一种钾通道开放剂？
Cardiovasc Res. 2009 Aug 1;83(3):417-8. doi: 10.1093/cvr/cvp193. Epub 2009 Jun 10.
7
Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.替米沙坦和氯沙坦对代谢综合征高血压患者胰岛素抵抗的影响。
Hypertens Res. 2007 Jan;30(1):49-53. doi: 10.1291/hypres.30.49.
8
Protecting endothelial function: A novel therapeutic target of ATP-sensitive potassium channel openers.
Cardiovasc Res. 2007 Feb 1;73(3):448-9. doi: 10.1016/j.cardiores.2006.11.014. Epub 2006 Nov 16.
9
Antihypertensive medications and the risk of incident type 2 diabetes.抗高血压药物与2型糖尿病发病风险
Diabetes Care. 2006 May;29(5):1065-70. doi: 10.2337/diacare.2951065.
10
Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.胰岛素抵抗与内皮功能障碍之间的相互关系：分子和病理生理机制。
Circulation. 2006 Apr 18;113(15):1888-904. doi: 10.1161/CIRCULATIONAHA.105.563213.
Zotero 插件